Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Saved in:
| Title: | Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. |
|---|---|
| Authors: | Delimpasi S; General Hospital Evangelismos, Athens, Greece., Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain., Auner HW; The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London, UK., Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Quach H; St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia., Pylypenko H; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine., Hájek R; Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic., Leleu X; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France., Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India., Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India., Venner CP; Cross Cancer Institute, Edmonton, Alberta, Canada., Benjamin R; Kings College Hospital NHS Foundation Trust, London, UK., Garg MK; University Hospitals of Leicester NHS Trust, Leicester, UK., Doronin V; City Clinical Hospital #40, Moscow, Russian Federation., Levy Y; Baylor University Medical Center, Dallas, Texas, USA., Moreau P; University of Nantes, Nantes, France., Chai Y; Karyopharm Therapeutics, Newton, Massachusetts, USA., Arazy M; Karyopharm Therapeutics, Newton, Massachusetts, USA., Shah J; Karyopharm Therapeutics, Newton, Massachusetts, USA., Shacham S; Karyopharm Therapeutics, Newton, Massachusetts, USA., Kauffman MG; Karyopharm Therapeutics, Newton, Massachusetts, USA., Richardson PG; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Grosicki S; Medical University of Silesia, Katowice, Poland. |
| Source: | American journal of hematology [Am J Hematol] 2022 Mar 01; Vol. 97 (3), pp. E83-E86. Date of Electronic Publication: 2021 Dec 29. |
| Publication Type: | Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34882831 AccessLevel: 2 PubType: Report PubTypeId: report PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Delimpasi+S%22">Delimpasi S</searchLink>; General Hospital Evangelismos, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Mateos+MV%22">Mateos MV</searchLink>; Hospital Universitario de Salamanca, Salamanca, Spain.<br /><searchLink fieldCode="AU" term="%22Auner+HW%22">Auner HW</searchLink>; The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Gavriatopoulou+M%22">Gavriatopoulou M</searchLink>; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Quach+H%22">Quach H</searchLink>; St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Pylypenko+H%22">Pylypenko H</searchLink>; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.<br /><searchLink fieldCode="AU" term="%22Hájek+R%22">Hájek R</searchLink>; Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Leleu+X%22">Leleu X</searchLink>; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22Dolai+TK%22">Dolai TK</searchLink>; Nil Ratan Sircar Medical College and Hospital, Kolkata, India.<br /><searchLink fieldCode="AU" term="%22Sinha+DK%22">Sinha DK</searchLink>; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India.<br /><searchLink fieldCode="AU" term="%22Venner+CP%22">Venner CP</searchLink>; Cross Cancer Institute, Edmonton, Alberta, Canada.<br /><searchLink fieldCode="AU" term="%22Benjamin+R%22">Benjamin R</searchLink>; Kings College Hospital NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Garg+MK%22">Garg MK</searchLink>; University Hospitals of Leicester NHS Trust, Leicester, UK.<br /><searchLink fieldCode="AU" term="%22Doronin+V%22">Doronin V</searchLink>; City Clinical Hospital #40, Moscow, Russian Federation.<br /><searchLink fieldCode="AU" term="%22Levy+Y%22">Levy Y</searchLink>; Baylor University Medical Center, Dallas, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Moreau+P%22">Moreau P</searchLink>; University of Nantes, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Chai+Y%22">Chai Y</searchLink>; Karyopharm Therapeutics, Newton, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Arazy+M%22">Arazy M</searchLink>; Karyopharm Therapeutics, Newton, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Shah+J%22">Shah J</searchLink>; Karyopharm Therapeutics, Newton, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Shacham+S%22">Shacham S</searchLink>; Karyopharm Therapeutics, Newton, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Kauffman+MG%22">Kauffman MG</searchLink>; Karyopharm Therapeutics, Newton, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Grosicki+S%22">Grosicki S</searchLink>; Medical University of Silesia, Katowice, Poland. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227610369%22">American journal of hematology</searchLink> [Am J Hematol] 2022 Mar 01; Vol. 97 (3), pp. E83-E86. <i>Date of Electronic Publication: </i>2021 Dec 29. – Name: TypePub Label: Publication Type Group: TypPub Data: Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7610369 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1096-8652 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203618609%22">03618609 </searchLink><i>NLM ISO Abbreviation: </i>Am J Hematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34882831 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/ajh.26434 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: E83 Titles: – TitleFull: Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Delimpasi S – PersonEntity: Name: NameFull: Mateos MV – PersonEntity: Name: NameFull: Auner HW – PersonEntity: Name: NameFull: Gavriatopoulou M – PersonEntity: Name: NameFull: Dimopoulos MA – PersonEntity: Name: NameFull: Quach H – PersonEntity: Name: NameFull: Pylypenko H – PersonEntity: Name: NameFull: Hájek R – PersonEntity: Name: NameFull: Leleu X – PersonEntity: Name: NameFull: Dolai TK – PersonEntity: Name: NameFull: Sinha DK – PersonEntity: Name: NameFull: Venner CP – PersonEntity: Name: NameFull: Benjamin R – PersonEntity: Name: NameFull: Garg MK – PersonEntity: Name: NameFull: Doronin V – PersonEntity: Name: NameFull: Levy Y – PersonEntity: Name: NameFull: Moreau P – PersonEntity: Name: NameFull: Chai Y – PersonEntity: Name: NameFull: Arazy M – PersonEntity: Name: NameFull: Shah J – PersonEntity: Name: NameFull: Shacham S – PersonEntity: Name: NameFull: Kauffman MG – PersonEntity: Name: NameFull: Richardson PG – PersonEntity: Name: NameFull: Grosicki S IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2022 Mar 01 Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1096-8652 Numbering: – Type: volume Value: 97 – Type: issue Value: 3 Titles: – TitleFull: American journal of hematology Type: main |
| ResultId | 1 |
